Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy (Q46417627)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

zoledronic acid

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

author name string

Brigitte Mlineritsch

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Gero Luschin-Ebengreuth

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Franz Kainberger

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Helmut Kässmann

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Jutta Claudia Piswanger-Sölkner

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Michael Seifert

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Ferdinand Ploner

8

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Christian Menzel

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Peter Dubsky

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Florian Fitzal

11

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Vesna Bjelic-Radisic

12

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Günther Steger

13

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Richard Greil

14

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Christian Marth

15

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Ernst Kubista

16

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Hellmut Samonigg

17

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Peter Wohlmuth

18

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Martina Mittlböck

19

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Raimund Jakesz

20

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Austrian Breast and Colorectal Cancer Study Group (ABCSG)

21

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

publication date

19 August 2008

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Lancet Oncology Commission

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

840-849

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 r

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Important determinants of bone strength: beyond bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density thresholds for pharmacological intervention to prevent fractures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(08)70204-3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18718815

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46417627&oldid=2110432304"